Eric Nadler, MD
Medical Oncology · Dallas, TXNPI 1134161243
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,184,977 of the $1,558,760 with a category attached, or 76.0%. 28 manufacturers reported payments, led by AstraZeneca at 29.7% of the total. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,223 payments — averaging $1274.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$463K
- Genentech USA, Inc.$206K
- Jazz Pharmaceuticals Inc.$152K
- Mirati Therapeutics, Inc.$105K
- G1 Therapeutics, Inc.$98K
- EMD Serono, Inc.$93K
- plus $443K from 22 others
Across 25 payments — averaging $60,205 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$858K
- AstraZeneca$444K
- Acerta Pharma LLC$129K
- Merck$71K
- Eli Lilly$4K
What the payments were for
- Consulting fees$195,96413%
- Speaking & faculty fees$1,184,97776%
- Travel & lodging$148,89010%
- Food & beverage$28,9002%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 377 | $462,631 |
| Genentech USA, Inc. | 146 | $205,528 |
| Jazz Pharmaceuticals Inc. | 127 | $152,389 |
| Mirati Therapeutics, Inc. | 82 | $104,584 |
| G1 Therapeutics, Inc. | 85 | $98,127 |
| EMD Serono, Inc. | 43 | $92,872 |
| Merck | 72 | $78,088 |
| Regeneron Healthcare Solutions, Inc. | 61 | $77,450 |
| Novocure Inc. | 43 | $48,523 |
| Sanofi | 32 | $36,344 |
| Pfizer | 11 | $33,174 |
| Lilly USA, LLC | 32 | $30,899 |
| Amgen | 31 | $29,581 |
| Daiichi Sankyo Inc. | 25 | $28,134 |
| Blueprint Medicines Corporation | 17 | $17,431 |
| Catalyst Pharmaceuticals, Inc. | 4 | $12,500 |
| Boehringer Ingelheim | 5 | $10,361 |
| AbbVie | 7 | $9,622 |
| Seagen Inc. | 2 | $8,000 |
| Eisai Inc. | 2 | $6,465 |
| Johnson & Johnson | 6 | $4,304 |
| E.r. Squibb & Sons, L.L.C. | 4 | $4,151 |
| Aadi Bioscience, Inc. | 1 | $3,500 |
| Rigel Pharmaceuticals, Inc. | 1 | $2,055 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $1,950 |
| Novartis | 3 | $46 |
| Gilead | 2 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$235,986
- TECENTRIQ$170,220
- IMFINZI$160,994
- ZEPZELCA$151,315
- LIBTAYO$112,253
- KRAZATI$103,832
- COSELA$97,018
- KEYTRUDA$62,635
- OPTUNE LUA (NOVOTTF-200T)$32,043
- Enhertu$31,438
- DATROWAY$30,257
- Alecensa$24,764
- LORBRENA$21,099
- GAVRETO$16,972
- RETEVMO$14,617
- ROZLYTREK$13,019
- FIRDAPSE$12,500
- EMRELIS$9,000
- IMDELLTRA (AMG 757)$8,899
- LENVIMA$6,465
How this compares
$1,558,760 in reported general payments places this provider in the 95th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AlecensaAlectinib Hcl | 14 | $146,371 |
| EliquisApixaban | 32 | $26,074 |
| XareltoRivaroxaban | 27 | $19,404 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 112 | $4,250 |
| Dexamethasone | 102 | $894 |
| Ondansetron OdtOndansetron | 75 | $852 |
| Prochlorperazine Maleate | 58 | $497 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 49 | $463 |
| Hydrocortisone | 20 | $261 |
| Levothyroxine Sodium | 37 | $236 |
| Gabapentin | 19 | $222 |
| Levofloxacin | 47 | $206 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 12 | $184 |
| Prednisone | 69 | $165 |
| Oxycodone Hcl | 19 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Alecensa | $205,528 | $146,37114 claims |
| PfizerEliquis | $33,174 | $26,07432 claims |
| Johnson & JohnsonXarelto | $4,304 | $19,40427 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Dallas
- Moshe LevyDallas$5.1M
- Andrew WhiteleyDallas$1.7M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Thomas HutsonDallas$944K
- Heather McArthurDallas$314K
- Tian ZhangDallas$286K
- Micah BurchDallas$221K
- David JohnsonDallas$212K
- Kartik KonduriDallas$191K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.